Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...
top of page
Subscriber login:
SUBMIT
Remember me
Search
Dec 24, 2021
Paths to Approval: Understanding U.S. Regulatory Pathways for Drug Products
This article details the potential regulatory approval pathways.
Dec 23, 2021
Potential Market Exclusivity Granted During U.S. Regulatory Approval Process
This article explains potential data and market exclusivity granted during the U.S. regulatory approval process.
Dec 22, 2021
Understanding the Process for FDA Approval and Expedited Review
This article details the FDA evaluation process and expedited review designations.
Dec 16, 2021
Medical Drug Coding And Reimbursement 101
This article explains medical drug coding and reimbursement.
Dec 15, 2021
Drug Pricing Part 2: Generic Drug Pricing
This article explains generic drug pricing, associated terms, including MAC rates and lists, biosimilar pricing, and more.
Dec 14, 2021
Drug Pricing Part 1: Key Terms, Stakeholders, and Brand Drug Pricing Processes
This article answers the question, "how does branded drug pricing work?" defining associated terms such as average wholesale price, wholesal
Nov 18, 2021
How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
Nov 1, 2021
IPD Executive Offers Perspective on Biosimilar Uptake and Policy
Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.
Nov 1, 2021
Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.
Oct 27, 2021
An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
Competitors in the field of adalimumab and insulin products may soon include authorized biologics.
Oct 22, 2021
AMCP Nexus 2021: A Wrap-Up
Biosimilar adoption and biosimilar market share were among the featured topics at the AMCP Nexus 2021 meeting in Denver, Colorado.
Oct 21, 2021
AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter
IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.
Apr 20, 2021
Further Dissecting the Launch of Adalimumab Biosimilars in the US
According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.
Apr 20, 2021
National Trends in Prescription Drug Expenditures and Projections for 2021
Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth
Oct 8, 2020
EY Announces Howard Krass of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Winner
Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.
May 15, 2020
Will COVID-19 Clog Generics, Biologics Pipeline?
IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.
Apr 29, 2020
IPD Analytics Experts Discuss Humira's Influence on Biosimilars
IPD Analytics experts discussed biosimilar competition on MJH Life Sciences News Network
Apr 26, 2020
IPD Analytics Experts Discuss the Insulin Pipeline
With conversion of the BLA pathway, new launches may receive interchangeability. New insulin products are being launched in the near future
Apr 22, 2020
Drug Pipeline for 2020 Strong in Generics, Biosimilars
According to interviewed experts at IPD Analytics, the 2020 drug pipeline includes a large number of generic launches.
Apr 20, 2020
A Look at the Generic and Biosimilar Drug Pipeline
IPD Analytics discussed both the generic and biosimilar drugs coming to market, and implications for managed care pharmacy at AMCP eLearning
Apr 20, 2020
AMCP Presenters Predict 4 More Biosimilar Launches in 2020
The pace of clinical trials have been affected by COVID-19, according to IPD Analytics' experts on the pharmaceutical pipeline.
Jan 23, 2020
Express Scripts Coverage, FDA Label Update Boost Rybelsus
There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.
Aug 12, 2019
Q&A, Part II: How Payers and Providers are Responding to the Biosimilar Market
Experts from IPD Analytics discuss payer management of biosimilars in the U.S. market.
bottom of page